Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel

Author： Torrisi Rosalba  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.62, Iss.4, 2008-09, pp. : 667-672

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment Strategies for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

By Yang Wei   Chamberlin Mary D.   Miller Todd W.  

The Journal of OncoPathology, Vol. 2, Iss. 2, 2014-06 ,pp. : 33-42

Optimal Clinical Ltd

Access to resources Recommend Favorite

Novel therapy for locally advanced triple-negative breast cancer

By                      

International Journal of Oncology, Vol. 47, Iss. 4, 2015-01 ,pp. : 1266-1272

Spandidos Publications

Access to resources Recommend Favorite

Preoperative Therapy Using Trastuzumab and Weekly Paclitaxel in a Stage III B Inoperable Locally Advanced HER2-Positive Breast Cancer with Complete Pathologic Response

By Rai Yoshiaki   Sagara Yoshiatsu   Ooi Yasuyo   Yasuaki   Sagara Yoshiaki   Baba Shinichi   Tamada Syugo   Matsuyama Yoshito   Ando Mitsutake  

Japanese Journal of Cancer and Chemotherapy, Vol. 36, Iss. 3, 2009-03 ,pp. : 471-473

Sunmedia

Access to resources Recommend Favorite

Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study

By Orditura Michele   Galizia Gennaro   Napolitano Vincenzo   Martinelli Erika   Pacelli Roberto   Lieto Eva   Aurilio Gaetano   Vecchione Loredana   Morgillo Floriana   Catalano Giuseppe   Ciardiello Fortunato   Genio Alberto Del   Martino Natale Di   De Vita Ferdinando  

Cancer Investigation, Vol. 28, Iss. 8, 2010-09 ,pp. : 820-827

Informa Healthcare

Access to resources Recommend Favorite

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

By Amadori Dino   Silvestrini Rosella   Lena Mario   Boccardo Francesco   Rocca Andrea   Scarpi Emanuela   Schittulli Francesco   Brandi Mario   Maltoni Roberta   Serra Patrizia   Ponzone Riccardo   Biglia Nicoletta   Gianni Lorenzo   Tienghi Amelia   Valerio Maria   Bonginelli Paola   Amaducci Laura   Faedi Marina   Baldini Editta   Paradiso Angelo  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 775-784

Springer Publishing Company

Access to resources Recommend Favorite